JP2020508329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508329A5 JP2020508329A5 JP2019546144A JP2019546144A JP2020508329A5 JP 2020508329 A5 JP2020508329 A5 JP 2020508329A5 JP 2019546144 A JP2019546144 A JP 2019546144A JP 2019546144 A JP2019546144 A JP 2019546144A JP 2020508329 A5 JP2020508329 A5 JP 2020508329A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric protein
- tim3
- cd40l
- domain
- ox40l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims description 63
- 108020001507 fusion proteins Proteins 0.000 claims description 63
- 239000003814 drug Substances 0.000 claims description 23
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 19
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 8
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 8
- 101000743493 Homo sapiens V-set and immunoglobulin domain-containing protein 8 Proteins 0.000 claims description 8
- 108091005906 Type I transmembrane proteins Proteins 0.000 claims description 8
- 108091005956 Type II transmembrane proteins Proteins 0.000 claims description 8
- 102100038355 V-set and immunoglobulin domain-containing protein 8 Human genes 0.000 claims description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- -1 41BBL Proteins 0.000 claims description 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 4
- 108010029697 CD40 Ligand Proteins 0.000 claims description 4
- 102100032937 CD40 ligand Human genes 0.000 claims description 4
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 4
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims description 4
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 claims description 4
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 102000000588 Interleukin-2 Human genes 0.000 claims description 4
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 4
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims description 4
- 108010042215 OX40 Ligand Proteins 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims description 4
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 4
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims description 4
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims description 4
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 claims description 4
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 4
- 210000005006 adaptive immune system Anatomy 0.000 claims description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 230000005909 tumor killing Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 7
- 210000005007 innate immune system Anatomy 0.000 claims 2
- 108050001049 Extracellular proteins Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 30
- 210000000987 immune system Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022130749A JP2022159510A (ja) | 2017-02-27 | 2022-08-18 | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464002P | 2017-02-27 | 2017-02-27 | |
| US62/464,002 | 2017-02-27 | ||
| PCT/US2018/020040 WO2018157165A1 (en) | 2017-02-27 | 2018-02-27 | Methods of making and using extracellular domain-based chimeric proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130749A Division JP2022159510A (ja) | 2017-02-27 | 2022-08-18 | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508329A JP2020508329A (ja) | 2020-03-19 |
| JP2020508329A5 true JP2020508329A5 (cg-RX-API-DMAC7.html) | 2021-04-08 |
| JP7128195B2 JP7128195B2 (ja) | 2022-08-30 |
Family
ID=63253416
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546149A Active JP7260477B2 (ja) | 2017-02-27 | 2018-02-27 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
| JP2019546144A Active JP7128195B2 (ja) | 2017-02-27 | 2018-02-27 | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
| JP2022130749A Pending JP2022159510A (ja) | 2017-02-27 | 2022-08-18 | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
| JP2023062366A Active JP7620045B2 (ja) | 2017-02-27 | 2023-04-06 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
| JP2025003769A Withdrawn JP2025061180A (ja) | 2017-02-27 | 2025-01-09 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546149A Active JP7260477B2 (ja) | 2017-02-27 | 2018-02-27 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130749A Pending JP2022159510A (ja) | 2017-02-27 | 2022-08-18 | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
| JP2023062366A Active JP7620045B2 (ja) | 2017-02-27 | 2023-04-06 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
| JP2025003769A Withdrawn JP2025061180A (ja) | 2017-02-27 | 2025-01-09 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
Country Status (15)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019009812A (es) | 2017-02-27 | 2019-10-14 | Shattuck Labs Inc | Proteinas quimericas basadas en tigit y light. |
| JP7511469B2 (ja) | 2017-09-27 | 2024-07-05 | イノザイム ファーマ， インコーポレイテッド | 組換えエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ（ｎｐｐ１）を使用して心血管機能を改善し、心血管疾患を処置するための方法。 |
| JP7439372B2 (ja) * | 2018-06-21 | 2024-02-28 | シャタック ラボ，インコーポレイテッド | ヘテロ二量体タンパク質及びその使用 |
| CN112912384A (zh) * | 2018-08-29 | 2021-06-04 | 沙塔克实验室有限公司 | 组合疗法 |
| CN112888706A (zh) * | 2018-08-29 | 2021-06-01 | 沙塔克实验室有限公司 | 包含基于tim-3的嵌合蛋白的组合疗法 |
| MX2021002292A (es) * | 2018-08-29 | 2021-05-27 | Shattuck Labs Inc | Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa. |
| EP3844280A4 (en) | 2018-08-31 | 2022-09-14 | Yale University | ENPP1 POLYPEPTIDES AND METHODS OF USE |
| MX2021002668A (es) * | 2018-09-05 | 2021-05-12 | Univ Arizona State | Plataforma de virus oncolitico para tratar el cancer hematologico. |
| KR102686295B1 (ko) | 2018-11-21 | 2024-07-19 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 아데노바이러스 및 아데노바이러스의 사용 방법 |
| WO2020176718A1 (en) * | 2019-02-28 | 2020-09-03 | Shattuck Labs, Inc. | Combination therapies |
| CN113710694A (zh) * | 2019-04-29 | 2021-11-26 | 梅奥医学教育及研究基金会 | 用于治疗癌症的多价pd-l1结合化合物 |
| CN112111437B (zh) * | 2020-05-25 | 2023-09-05 | 江南大学 | 2’-岩藻糖基乳糖产量提高的重组枯草芽孢杆菌及其构建方法 |
| KR20230019152A (ko) * | 2020-06-02 | 2023-02-07 | 아르커스 바이오사이언시즈 인코포레이티드 | Tigit에 대한 항체 |
| IL298946A (en) | 2020-06-18 | 2023-02-01 | Genentech Inc | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| CN111808800B (zh) * | 2020-07-20 | 2022-08-26 | 中南大学湘雅二医院 | 一种体外诱导免疫抑制性髓系抑制细胞及其制备和应用 |
| WO2022061124A1 (en) * | 2020-09-17 | 2022-03-24 | Shattuck Labs, Inc. | Clinical dosing of sirp1a chimeric protein |
| EP4237000A4 (en) * | 2020-11-02 | 2024-09-18 | Athae Bio, Inc. | TWO-DOMAIN MULTIMERIC FUSION PROTEINS |
| CA3201215A1 (en) * | 2020-12-03 | 2022-06-09 | Taylor Schreiber | Method of determining resistance to checkpoint inhibitor therapies |
| CN116897202A (zh) * | 2021-02-24 | 2023-10-17 | 科济生物医药（上海）有限公司 | Tigit工程化细胞及其组合物 |
| CN115260312B (zh) * | 2021-04-30 | 2025-02-14 | 保诺科技（北京）有限公司 | 结合ox40的抗体或抗原结合片段 |
| WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| CN115960247A (zh) * | 2021-10-13 | 2023-04-14 | 苏州科锐迈德生物医药科技有限公司 | 基于t7rna聚合酶的融合多肽及其制备方法、用途 |
| IL312504A (en) * | 2021-11-01 | 2024-07-01 | Shattuck Labs Inc | Tailored mRNA therapies |
| CN114209815B (zh) * | 2021-11-22 | 2024-04-26 | 山东大学 | 一种药物组合物及其制备方法和应用 |
| WO2023105281A1 (en) * | 2021-12-11 | 2023-06-15 | Fundaciò Privada Institut De Recerca De La Sida-Caixa | Soluble tigit recombinant proteins |
| CN115490771A (zh) * | 2021-12-24 | 2022-12-20 | 合肥天港免疫药物有限公司 | 重组抗体及其应用 |
| CN114196691B (zh) * | 2021-12-28 | 2023-08-11 | 重庆澳龙生物制品有限公司 | 一种制备防治牛、羊棘球蚴病多表位重组疫苗的基因、蛋白质、疫苗和应用 |
| KR20250022049A (ko) | 2022-06-07 | 2025-02-14 | 제넨테크, 인크. | 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법 |
| CN117624375A (zh) * | 2022-08-30 | 2024-03-01 | 北京卡替医疗技术有限公司 | 增强受体、表达增强受体的免疫细胞及其用途 |
| CN116350748A (zh) * | 2022-11-01 | 2023-06-30 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | Tigit融合蛋白在制备用于治疗系统性红斑狼疮药物中的应用 |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
| CN116041542A (zh) * | 2022-12-06 | 2023-05-02 | 上海恩凯细胞技术有限公司 | 逆转肿瘤微环境抑制性信号的nk细胞制备方法及应用 |
| CN116037072B (zh) * | 2023-02-24 | 2025-01-03 | 宁夏医科大学 | 一种血清抗体亲和分离材料的制备方法与应用 |
| CN116925236B (zh) * | 2023-05-12 | 2024-06-04 | 上海恩凯细胞技术有限公司 | 嵌合转换受体及其应用 |
| WO2024260419A1 (en) * | 2023-06-22 | 2024-12-26 | Fbd Biologics Limited | Multi-targeting protein complex and methods of use thereof |
| CN116982600B (zh) * | 2023-09-14 | 2025-11-18 | 江苏集萃药康生物科技股份有限公司 | 一种cd69人源化小鼠模型的构建方法及其应用 |
| CN119930791A (zh) * | 2023-11-02 | 2025-05-06 | 重庆精准生物技术有限公司 | 特异性tigit肽段 |
| WO2025140345A1 (zh) * | 2023-12-29 | 2025-07-03 | 沈阳三生制药有限责任公司 | 一种tigit多肽及tigit/ctla4融合蛋白 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| JP3308534B2 (ja) | 1991-10-25 | 2002-07-29 | イミュネックス・コーポレーション | 新規なサイトカイン |
| US20110041190A1 (en) | 2002-10-31 | 2011-02-17 | Tykocinski Mark L | Novel chimeric proteins |
| US7569663B2 (en) | 2000-01-03 | 2009-08-04 | Mark L. Tykocinski | Chimeric proteins and methods for using the same |
| US7696168B2 (en) | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| KR20060089732A (ko) | 2003-10-03 | 2006-08-09 | 브라이엄 앤드 위민즈 하스피틀 | Ｔｉｍ-3 리간드 및 그의 방법 |
| RU2356909C2 (ru) | 2003-11-13 | 2009-05-27 | Ханми Фарм. Инд. Ко., Лтд. | Белковый комплекс, полученный с использованием фрагмента иммуноглобулина, и способ получения такого комплекса |
| JP2006345852A (ja) | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
| JP2009537145A (ja) | 2006-05-15 | 2009-10-29 | バイラル ロジック システムズ テクノロジー コーポレーション | 免疫学的疾患および障害を治療するためのｃｄ４７と関連した組成物および方法 |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| EP2038303A2 (en) | 2006-06-21 | 2009-03-25 | Genentech, Inc. | Crystal structure of ox40l and ox40l complexed with ox40 receptor |
| WO2008061377A1 (en) | 2006-11-22 | 2008-05-29 | Centre Hospitalier De L'universite De Montreal | Novel receptor for cd40l and uses thereof |
| WO2008144029A1 (en) | 2007-05-14 | 2008-11-27 | The University Of Chicago | Antibody-light fusion products for cancer therapeutics |
| PT3056515T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| EP2262531A1 (en) | 2008-03-08 | 2010-12-22 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| SG191698A1 (en) | 2008-06-30 | 2013-07-31 | Univ Pennsylvania | Fn14/trail fusion proteins |
| CA2729810A1 (en) | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | Tgf-.beta. antagonist multi-target binding proteins |
| JP5674155B2 (ja) | 2008-07-21 | 2015-02-25 | アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ | Ｔｎｆｓｆ一本鎖分子 |
| WO2010062401A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
| WO2010062399A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Csf1r extracellular domain fusion molecules and treatments using same |
| EA201100947A1 (ru) * | 2008-12-19 | 2012-02-28 | Новартис Аг | Растворимые полипептиды, предназначенные для применения при лечении аутоиммунных и воспалительных нарушений |
| CN103641918A (zh) | 2009-03-13 | 2014-03-19 | 宾夕法尼亚大学董事会 | Ox40/trail融合蛋白 |
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| EP2621514B1 (en) | 2010-09-28 | 2016-09-21 | KAHR Medical (2005) Ltd | Compositions and methods for treatment of hematological malignancies |
| WO2012062218A1 (en) | 2010-11-11 | 2012-05-18 | The University Of Hong Kong | Soluble pd-1 variants, fusion constructs, and uses thereof |
| SI2697257T1 (sl) | 2011-04-13 | 2017-02-28 | Bristol-Myers Squibb Company | FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve |
| US10179164B2 (en) | 2011-05-25 | 2019-01-15 | Cel-Sci Corporation | Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions |
| CN102850458B (zh) * | 2011-06-28 | 2014-10-01 | 华博生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
| EA201490364A1 (ru) | 2011-07-29 | 2014-08-29 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Костимулирующие рецепторы-переключатели |
| EP2812022B1 (en) | 2012-02-06 | 2019-06-26 | Providence Health & Services - Oregon | Method of monitoring cancer treatment using ox40 agonists |
| CA3004695C (en) | 2012-04-30 | 2020-08-04 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
| EP2850106B1 (en) | 2012-05-18 | 2022-03-23 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
| CN103566377A (zh) | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| SI2931752T1 (sl) | 2012-12-17 | 2019-12-31 | Trillium Therapeutics Inc. | Zdravljenje bolezenskih celic CD47+ s fuzijami ALFA-FC SIRP |
| CN105026424A (zh) | 2013-01-01 | 2015-11-04 | 卡尔医疗有限公司 | 稳定形式的信号转化蛋白融合蛋白、及其使用和制备的方法 |
| WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| US9873747B2 (en) | 2013-01-31 | 2018-01-23 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| US9834610B2 (en) | 2013-01-31 | 2017-12-05 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector T cells |
| WO2015116178A1 (en) | 2014-01-31 | 2015-08-06 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector t cells |
| US9657082B2 (en) | 2013-01-31 | 2017-05-23 | Thomas Jefferson University | PD-L1 and PD-L2-based fusion proteins and uses thereof |
| US10533054B2 (en) | 2013-01-31 | 2020-01-14 | Thomas Jefferson University | Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system |
| EP3811954A1 (en) | 2013-02-26 | 2021-04-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| CA2902830C (en) | 2013-03-12 | 2023-09-19 | Biocon Ltd. | Fusion immunomodulatory proteins and methods for making same |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| US10144770B2 (en) * | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| US10196435B2 (en) | 2013-11-18 | 2019-02-05 | University Of Southern California | OX40L fusion protein for the immunotherapy of tumors of veterinary animals |
| EP3527587A1 (en) | 2013-12-17 | 2019-08-21 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists |
| AU2015205530B8 (en) | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| EP3094651B1 (en) | 2014-01-14 | 2020-03-11 | Kymab Limited | Anti-light antibodies |
| CA2936244A1 (en) | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions and methods for modulating and redirecting immune responses |
| KR102314088B1 (ko) | 2014-03-24 | 2021-10-15 | 이뮨원코 바이오파마슈티컬즈 (상하이) 컴퍼니 리미티드 | 새로운 이중 기능성의 재조합 융합 단백질, 이의 제조 방법 및 용도 |
| CN106456734A (zh) | 2014-05-29 | 2017-02-22 | 免疫医疗有限责任公司 | Ox40l融合蛋白及其用途 |
| EP3160497A4 (en) | 2014-06-27 | 2018-01-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Conjugates for immunotherapy |
| GB2532619A (en) | 2014-08-08 | 2016-05-25 | Alexo Therapeutics Int | Sirp-Alpha Variant Constructs And Uses Thereof |
| SI3482766T1 (sl) | 2014-08-11 | 2020-09-30 | Delinia, Inc. | Spremenjene variante IL-2, ki selektivno aktivirajo regulatorne T celice za zdravljenje avtoimunskih bolezni |
| HUE046661T2 (hu) | 2014-08-15 | 2020-03-30 | Merck Patent Gmbh | SIRP-alfa immunglobulin fúziós proteinek |
| KR20170096112A (ko) | 2014-11-17 | 2017-08-23 | 제넨테크, 인크. | Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법 |
| CA2969730A1 (en) | 2014-12-05 | 2016-06-09 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
| WO2016112983A1 (en) * | 2015-01-15 | 2016-07-21 | Biontech Ag | Cytokine fusion proteins |
| WO2016126608A1 (en) * | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| KR20170109582A (ko) | 2015-02-06 | 2017-09-29 | 히트 바이오로직스, 인코퍼레이티드 | 벡터 공동 발현 백신 및 공동 자극 분자 |
| WO2016166139A1 (en) * | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
| CA2994935A1 (en) | 2015-05-18 | 2016-11-24 | Ab Initio Biotherapeutics, Inc. | Sirp polypeptide compositions and methods of use |
| ES2881771T3 (es) | 2015-08-07 | 2021-11-30 | Alx Oncology Inc | Constructos que tienen un dominio de SIRP-alfa o variante del mismo |
| RU2022102624A (ru) * | 2015-10-01 | 2022-03-10 | Хит Байолоджикс, Инк. | Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков |
| EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
| MX2019009812A (es) * | 2017-02-27 | 2019-10-14 | Shattuck Labs Inc | Proteinas quimericas basadas en tigit y light. |
-
2018
- 2018-02-27 MX MX2019009812A patent/MX2019009812A/es unknown
- 2018-02-27 CN CN202410811167.XA patent/CN118994414A/zh active Pending
- 2018-02-27 CN CN201880013956.1A patent/CN110381983B/zh active Active
- 2018-02-27 BR BR112019017298A patent/BR112019017298A2/pt unknown
- 2018-02-27 US US16/484,850 patent/US20190367579A1/en not_active Abandoned
- 2018-02-27 KR KR1020197023430A patent/KR102745835B1/ko active Active
- 2018-02-27 EP EP18756868.8A patent/EP3585418A4/en not_active Withdrawn
- 2018-02-27 CA CA3054127A patent/CA3054127A1/en active Pending
- 2018-02-27 IL IL313003A patent/IL313003A/en unknown
- 2018-02-27 MY MYPI2019004825A patent/MY207687A/en unknown
- 2018-02-27 WO PCT/US2018/020040 patent/WO2018157165A1/en not_active Ceased
- 2018-02-27 WO PCT/US2018/020037 patent/WO2018157162A1/en not_active Ceased
- 2018-02-27 IL IL268198A patent/IL268198B2/en unknown
- 2018-02-27 CA CA3054133A patent/CA3054133A1/en active Pending
- 2018-02-27 JP JP2019546149A patent/JP7260477B2/ja active Active
- 2018-02-27 JP JP2019546144A patent/JP7128195B2/ja active Active
- 2018-02-27 US US16/484,852 patent/US11332509B2/en active Active
- 2018-02-27 CN CN201880009524.3A patent/CN110234345A/zh active Pending
- 2018-02-27 EP EP18757341.5A patent/EP3585425A4/en not_active Withdrawn
- 2018-02-27 SG SG11201906465YA patent/SG11201906465YA/en unknown
- 2018-02-27 AU AU2018223821A patent/AU2018223821B2/en active Active
-
2019
- 2019-06-28 PH PH12019501533A patent/PH12019501533A1/en unknown
- 2019-08-20 ZA ZA2019/05488A patent/ZA201905488B/en unknown
-
2020
- 2020-04-24 US US16/857,787 patent/US10899817B2/en active Active
- 2020-09-10 US US17/017,108 patent/US10927159B2/en active Active
-
2022
- 2022-04-06 US US17/714,912 patent/US20220227831A1/en not_active Abandoned
- 2022-04-11 US US17/717,740 patent/US12071465B2/en active Active
- 2022-08-18 AU AU2022218575A patent/AU2022218575A1/en not_active Abandoned
- 2022-08-18 JP JP2022130749A patent/JP2022159510A/ja active Pending
-
2023
- 2023-04-06 JP JP2023062366A patent/JP7620045B2/ja active Active
-
2024
- 2024-03-04 US US18/594,400 patent/US20240190939A1/en not_active Abandoned
- 2024-07-17 US US18/775,288 patent/US20240368242A1/en active Pending
-
2025
- 2025-01-09 JP JP2025003769A patent/JP2025061180A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508329A5 (cg-RX-API-DMAC7.html) | ||
| JP2020508068A5 (cg-RX-API-DMAC7.html) | ||
| JP5897035B2 (ja) | 汎用の抗タグキメラ抗原受容体発現ｔ細胞及びがんを治療する方法 | |
| JP2021191273A (ja) | 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法 | |
| IL258029B (en) | Compounds and methods for joining extracellular complexes of type 1 and 2 as heterologous chimeric proteins | |
| JP2018529363A5 (cg-RX-API-DMAC7.html) | ||
| US20160347814A1 (en) | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases | |
| KR20210013160A (ko) | 다중-특이적 결합 단백질 및 그에 대한 개선 | |
| JP6242484B2 (ja) | 特定の改善されたヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子 | |
| JP2018521008A (ja) | 腫瘍形成を処置するための治療用組成物および治療方法 | |
| RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
| TW201008580A (en) | Dual variable domain immunoglobulin and uses thereof | |
| TW201006485A (en) | Dual variable domain immunoglobulins and uses thereof | |
| TW201109438A (en) | Dual variable domain immunoglobulins and uses thereof | |
| CN103282380A (zh) | 红细胞结合性治疗剂 | |
| CN112912400B (zh) | Nk接合子分子及其使用方法 | |
| JP6154895B2 (ja) | ヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子 | |
| TW200922616A (en) | FOXM1 peptide and medicinal agent comprising the same | |
| JP2023536651A (ja) | Ｉｌ２７受容体結合に関連する組成物および方法 | |
| CN103965363A (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2020508063A5 (cg-RX-API-DMAC7.html) | ||
| CA3044424C (en) | Fractal combination therapy | |
| CN102725311A (zh) | 治疗发炎的方法 | |
| JP6933724B2 (ja) | Ｎｋ細胞活性化融合タンパク質、ｎｋ細胞およびそれらを含む医薬組成物 | |
| JP6980196B2 (ja) | Ｈｌａ−ｂ５７オープンコンフォーマー |